

Inify Laboratories AB (publ) – Bulletin from the Annual General Meeting 2026

Inify Laboratories AB, corp. no. 559345-4431, held its ordinary Shareholders' Annual General Meeting on May 20, 2026. The AGM resolved, with the required majority, on all matters in accordance with the Board of Directors's published proposal. Below is a summary of the main resolutions, for further details please refer to the notice available on the company's website.

Adoption of the accounts

The Annual General Meeting adopted the balance sheet and income statement as well as the consolidated balance sheet and consolidated income statement for the period January 1, 2025 – December 31, 2025.

Disposition of financial results

The Annual General Meeting resolved, in accordance with the Board of Director's proposal, that the loss for the year be distributed according to the balance sheet.

Discharge from liability

The members of the Board of Directors and the CEO were discharged from liability.

Remuneration and auditors fees

Remuneration to the Board of Directors and auditors was resolved as follows:

- Remuneration to the Chairman of the Board is SEK 325,000 for the period until next AGM.
- Remuneration to other board members, who are not principal owners, is SEK 225,000 for the period until next AGM.
- Remuneration to the auditor is paid against invoice, after approval by the company.

Board of Directors and auditor

Board members Olof Sandén, Martin Ingvar and Magne Jordanger were re-elected as board members. Grant Thornton Sweden AB was re-elected as audit firm with Joakim Söderin as acting auditor.

For more information, please contact CEO Fredrik Palm (fredrik.palm@inify.com) or visit <https://www.inify.com>

About Inify Laboratories

The future of diagnostics

Inify Laboratories offers diagnostics through specialised laboratory services in histopathology, with a focus on streamlining patient pathways. The company performs clinical diagnostics in prostate cancer and gastroenterology, providing an integrated service that spans from early sample handling to final diagnosis. The laboratory system is scalable both in handling large volumes of patient samples and for replicating in new locations.

Quality and response times are optimised in every step - from logistics to tissue preparation and diagnosis - using a fully digital, standardised and AI-assisted workflow. The diagnosis is always performed by a pathologist and is assisted by Inify's proprietary AI, proven to have world-leading precision in clinical

evaluations. The entire workflow is supported by a tailor-made system that also enables development to include additional diagnostic areas.

Inify Laboratories is an international group headquartered in Stockholm, Sweden, with local laboratories in Sweden and the UK. The company's share is listed on Euronext Growth Oslo under the ticker INIFY.

This information is subject to the disclosure requirements of sections 5-12 of the Norwegian Securities Trading Act.